Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2002 Nov;93(11):1250–1257. doi: 10.1111/j.1349-7006.2002.tb01231.x

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

Masaki Fujimura 1,✉, Noriyuki Katsumata 2, Hiroshi Tsuda 3, Naoko Uchi 1, Satomi Miyazaki 1, Takao Hidaka 1, Masatoshi Sakai 1, Shigeru Saito 1
PMCID: PMC5926901  PMID: 12460467

Abstract

Ovarian clear cell adenocarcinoma (CCA) is generally chemo‐resistant. Recently the poor prognosis and resistance to chemotherapeutic agents of HER2/neu over‐expressing tumors have become clear. Thus, we investigated the expression level of HER2 in surgically resected CCA and ovarian serous adenocarcinoma, endometrioid adenocarcinoma, and mucinous adenocarcinoma specimens, as well as CCA cell lines, by an immunohistochemical method. HER2 was over‐expressed in 42.9% of CCA (P=0.026, vs. ovarian serous adenocarcinoma), 20.8% of ovarian serous adenocarcinoma, 23.1% of ovarian endometrioid adenocarcinoma, and 30.0% of mucinous adenocarcinoma specimens. Three CCA cell lines, RMG‐1, HAC‐II and KK were also positively stained for HER2. A flow‐cytometric study of HER2 revealed 7.2‐, 6.4‐ and 4.5‐fold greater expression of HER2 than that of normal mammary gland, respectively. Trastuzumab, a humanized recombinant monoclonal antibody against HER2 significantly and dose‐dependently reduced the growth of CCA cell lines in vitro. The extent of the inhibitory effect of trastuzumab was dependent on the expression level of HER2. Trastuzumab also dose‐dependently inhibited the growth of xenografted RMG‐1 tumor. The survival period of trastuzumab‐treated mice was longer than that of the control group. From these findings, trastuzumab appears to be a candidate as a treatment modality for HER2 over‐expressing ovarian CCA.

Keywords: Ovarian clear cell adenocarcinoma, HER2, Trastuzumab, HERCEPTIN, Growth inhibition

Full Text

The Full Text of this article is available as a PDF (1.8 MB).

REFERENCES

  • 1. ) Brescia , R. J. , Dubin , N. and Demopoulos , R. I.Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival . Int. J. Gynecol. Pathol. , 6 , 287 – 293 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Jenison , E. L. , Montag , A. G. , Griffiths , C. T. , Welch , W. R. , Lavin , P. T. , Greer , J. and Knapp , R. C.Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma . Gynecol. Oncol. , 32 , 65 – 71 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Kita , T. , Kikuchi , Y. , Kudoh , K. , Takano , M. , Goto , T. , Hirata , J. , Tode , T. and Nagata , I.Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary . Oncol. Rep. , 7 , 327 – 331 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Komiyama , S. , Aoki , D. , Tominaga , E. , Susumu , N. , Udagawa , Y. and Nozawa , S.Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation . Gynecol. Oncol. , 72 , 342 – 346 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Fujimura , M. , Yamakawa , Y. , Hidaka , T. , Kataoka , K. , Akada , S. , Teranishi , A. and Saito , S.Absence of estrogen receptor‐α expression in human ovarian clear cell adenocarcinoma compared with ovarian serous and endometrioid adenocarcinoma . Am. J. Surg. Pathol. , 25 , 667 – 672 ( 2001. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Cutolo , M. , Sulli , A. , Seriolo , B. , Accardo , S. and Massy , A. T.Estrogens, the immune response and autoimmunity . Clin. Exp. Rheumatol. , 13 , 217 – 226 ( 1995. ). [PubMed] [Google Scholar]
  • 7. ) Bouras , T. , Southey , M. C. and Venter , D. J.Over‐expression of the steroid receptor coactivator AIB1 in breast cancer correlates with absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu . Cancer Res. , 61 , 903 – 907 ( 2001. ). [PubMed] [Google Scholar]
  • 8. ) King , C. R. , Kraus , M. H. and Aaronson , S. A.Amplification of a novel v‐erbB‐related gene in a human mammary carcinoma . Science , 229 , 974 – 976 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Rolitsky , C. D. , Theil , K. S. , McGaughy , V. R. , Copeland , L. J. and Niemann , T. H.HER2/neu amplification and overexpression in endometrial carcinoma . Int. J. Gynecol. Pathol. , 18 , 138 – 143 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Kim , Y. C. , Park , K. O. , Kern , J. A. , Park , C. S. , Lim , S. C. , Jang , A. S. and Yang , J. B.The interactive effect of Ras, HER2, P53 and Bcl‐2 expression in predicting the survival of non‐small cell lung cancer patients . Lung Cancer , 22 , 181 – 190 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Sato , K. , Moriyama , M. , Mori , S. , Saito , M. , Watanuki , T. , Terada , K. , Okuhara , E. , Akiyama , T. , Toyoshima , K. and Yamamoto , T.An immunohistologic evaluation of c‐erbB‐2 gene product in patients with urinary bladder carcinoma . Cancer , 70 , 2493 – 2499 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Press , M. F. , Pike , M. C. , Hung , G. , Zhou , J. Y. , Ma , Y. , George , J. , Dietz‐Band , J. , James , W. , Slamon , D. J. and Batsakis , J. G.Amplification and overexpression of HER2/neu in carcinoma of the salivary gland: correlation with poor prognosis . Cancer Res. , 54 , 5675 – 5682 ( 1994. ). [PubMed] [Google Scholar]
  • 13. ) Lei , S. , Appert , H. E. , Nakata , B. , Domenico , D. R. , Kim , K. and Howard , J. M.Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival . Int. J. Pancreatol. , 17 , 15 – 21 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Slamon , D. J. , Leyland‐Jones , B. , Shak , S. , Fuchs , H. , Paton , V. , Bajamonde , A. , Fleming , T. , Eiermann , W. , Wolter , J. , Pegram , M. , Baselga , J. and Norton , L.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N. Engl. J. Med. , 344 , 783 – 792 ( 2001. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Fornier , M. , Esteva , F. J. and Seidman , A. D.Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer . Semin. Oncol. , 27 , 38 – 45 ( 2000. ). [PubMed] [Google Scholar]
  • 16. ) Sasa , H. , Ishii , K. , Hirata , J. , Kikuchi , Y. , Nagata , I. , Kawai , T. , Senoo , A. , Sugita , M. , Sugishita , T. and Tenjin , Y.Establishment and characterization of a CA‐125‐producing human ovarian clear cell carcinoma cell line . Hum. Cell , 6 , 279 – 286 ( 1993. ). [PubMed] [Google Scholar]
  • 17. ) Kiguchi , K. , Iwamori , M. , Mochizuki , Y. , Kishikawa , T. , Tsukazaki , K. , Saga , M. , Amemiya , A. and Nozawa , S.Selection of human ovarian carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Lex‐determinant in the dissemination potential . Jpn. J. Cancer Res. , 89 , 923 – 932 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. ) Nishida , M. and Iwasaki , H.Establishment of a human ovarian clear‐cell carcinoma cell line (HAC‐2 cell) in vitro . Hum. Cell , 1 , 345 – 346 ( 1988. ). [Google Scholar]
  • 19. ) Fujimura , M. , Kataoka , K. , Hidaka , T. and Saito , S.Effect of anti‐cancer agents in ovarian clear cell adenocarcinoma . Oncol. Chemother. , 16 , 241 – 244 ( 2000. ) (in Japanese) . [Google Scholar]
  • 20. ) Hatanaka , Y. , Hashizume , K. , Kamihara , Y. , Itoh , H. , Tsuda , H. , Osamura , R. Y. and Tani , Y.Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest(tm) in breast carcinoma by image analysis . Pathol. Int. , 51 , 33 – 36 ( 2001. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Sarup , J. C. , Johnson , R. M. , King , K. L. , Fendly , B. M. , Lipari , M. T. , Napier , M. A. , Ullrich , A. and Shepard , H. M.Characterization of an anti‐p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth . Growth Regul. , 1 , 72 – 82 ( 1991. ). [PubMed] [Google Scholar]
  • 22. ) Houchens , D. P. , Ovejera , A. A. and Barker , A. D.The therapy of human tumors in athymic (nude) mice . In “ Proc. Symp. The Use of Athymic (Nude) Mice in Cancer Research ,” ed. Houchens D. P. and Ovejera A. A. , pp. 267 ( 1978. ). Gustav Fisher; , New York . [Google Scholar]
  • 23. ) Berns , E. M. , Klijn , J. G. , van Staveren , I. L. , Portengen , H. , Noordegraaf , E. and Foekens , J. A.Prevalence of amplification of the oncogenes c‐myc, HER2/neu, and int‐2 in one thousand human breast tumours: correlation with steroid receptors . Eur. J. Cancer , 28 , 697 – 700 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Slamon , D. J. , Godolphin , W. , Jones , L. A. , Holt , J. A. , Wong , S. G. , Keith , D. E. , Levin , W. J. , Stuart , S. G. , Udove , J. , Ullrich , A. and Press , M. F.Studies of the HER2/neu protooncogene in human breast and ovarian cancer . Science , 244 , 707 – 712 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Rolitsky , C. D. , Theil , K. S. , McGaughy , V. R. , Copeland , L. J. and Niemann , T. H.HER2/neu amplification and overexpression in endometrial carcinoma . Int. J. Gynecol. Pathol. , 18 , 138 – 143 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Kern , J. A. , Schwartz , D. A. , Nordberg , J. E. , Weiner , D. B. , Greene , M. I. , Torney , L. and Robinson , R. A.P185neu expression in human lung adenocarcinomas predicts shortened survival . Cancer Res. , 50 , 5184 – 5187 ( 1990. ). [PubMed] [Google Scholar]
  • 27. ) Jaehne , J. , Urmacher , C. , Thaler , H. T. , Friedlander‐Klar , H. , Cordon‐Cardo , C. and Meyer , H. J.Expression of Her2/neu oncogene product p185 in correlation to clinico‐pathological and prognostic factors of gastric carcinoma . J. Cancer Res. Clin. Oncol. , 118 , 474 – 479 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) D'Emilia , J. , Bulovas , K. , D'Ercole , K. , Wolf , B. , Steele , G. and Summerhayes , I. C.Expression of the c‐erbB‐2 gene product (p185) at different stages of neoplastic progression in the colon . Oncogene , 4 , 1233 – 1239 ( 1989. ). [PubMed] [Google Scholar]
  • 29. ) Al‐Kasspooles , M. , Moore , J. H. , Orringer , M. B. and Beer , D. G.Amplification and over‐expression of the ECFR and serbB‐2 genes in human esophageal adenocarcinomas . Int. J. Cancer , 54 , 213 – 219 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Neal , D. E. , Marsh , C. , Bennett , M. K. , Abel , P. D. , Hall , R. R. , Sainsbury , J. R. and Harris , A. L.Epidermal‐growth‐factor receptors in human bladder cancer: comparison of invasive and superficial tumors . Lancet , i , 366 – 368 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Lei , S. , Appert , H. E. , Nakata , B. , Domenico , D. R. , Kim , K. and Howard , J. M.Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened surival . Int. J. Pancreatol. , 17 , 15 – 21 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Seki , A. , Yoshinouchi , M. , Seki , N. , Kodama , J. , Miyagi , Y. and Kudo , T.Detection of c‐erbB‐2 and FGF‐3 (INT‐2) gene amplification in epithelial ovarian cancer . Int. J. Oncol. , 17 , 103 – 106 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Afify , A. M. , Werness , B. A. and Mark , H. F.HER‐2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma . Exp. Mol. Pathol. , 66 , 163 – 169 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Kim , Y. T. , Kim , J. W. and Lee , J. W.c‐erbB‐2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors . Cancer Lett. , 132 , 91 – 97 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Rolitsky , C. D. , Theil , K. S. , McGaughy , V. R. , Copeland , L. J. and Niemann , T. H.HER‐2/neu amplification and overexpression in endometrial carcinoma . Int. J. Gynecol. Pathol. , 18 , 138 – 143 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Leitzel , K. , Teramoto , Y. , Konrad , K. , Chinchilli , V. M. , Volas , G. , Grossberg , H. , Harvey , H. , Demers , L. and Lipton , A.Elevated serum c‐erbB‐2 antigen levels and decreased response to hormone therapy of breast cancer . J. Clin. Oncol. , 13 , 1129 – 1135 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Berns , E. M. , Foekens , J. A. , van Staveren , I. L. , van Putten , W. L. , de Koning , H. Y. , Portengen , H. Z. and Klijn , J. G.Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment . Gene , 159 , 11 – 18 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 38. ) Bianco , A. R. , de Laurentis , M. , Carlomagno , C. , Lauria , R. , Petrella , G. , Panico , L. , Pettinato , G. , Perrone , F. , Gallo , C. , Marinelli , A. and De Placido , S.20 year update of the Naples gun trial of adjuvant breast cancer therapy: evidence of interaction between c‐erbB‐2 expression and tamoxifen efficacy . Proc. Am. Soc. Clin. Oncol. , 17 , 97a ( 1998. ). [Google Scholar]
  • 39. ) Yamauchi , H. , O'Neill , A. , Gelman , R. , Carney , W. , Tenney , D. Y. , Hosch , S. and Hayes , D. F.Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER2/c‐neu protein . J. Clin. Oncol. , 15 , 2518 – 2525 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 40. ) Pietras , R. J. , Arboleda , J. , Reese , D. M. , Wongvipat , N. , Pegram , M. D. , Ramos , L. , Gorman , C. M. , Parker , M. G. , Sliwkowski , M. X. and Slamon , D. J.HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone‐independent growth in human breast cancer cells . Oncogene , 10 , 2435 – 2446 ( 1995. ). [PubMed] [Google Scholar]
  • 41. ) Benz , C. C. , Scott , G. K. , Sarup , J. C. , Johnson , R. M. , Tripathy , D. , Coronado , E. , Shepard , H. M. and Osborne , C. K.Estrogen‐dependent, tamoxifen‐resistant tumorigenic growth of MCF‐7 cells transfected with HER2/neu . Breast Cancer Res. Treat. , 24 , 85 – 95 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 42. ) Bertram , J. , Killian , M. , Brysch , W. , Schlingensiepen , K. H. and Kneba , M.Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA‐specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides . Biochem. Biophys. Res. Commun. , 200 , 661 – 667 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 43. ) Cooler , R. , Lupus , R. , Backs , S. S. and Gelmann , E. P.ErbB‐2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB‐2 oncogene amplification . Br. J. Cancer , 70 , 819 – 825 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. ) Hudziak , R. M. , Lewis , G. D. , Winget , M. , Fendly , B. M. , Shepard , H. M. and Ullrich , S. A.P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor . Mol. Cell. Biol. , 9 , 1165 – 1172 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. ) Pegram , M. D. , Lipton , A. , Hayes , D. F. , Weber , B. L. , Baselga , J. M. , Tripathy , D. , Baly , D. , Baughman , S. A. , Twaddell , T. , Glaspy , J. A. and Slamon , D. J.Phase II study of receptor‐enhanced chemosensitivity using recombinant humanized anti‐p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu‐overexpressing meta‐static breast cancer refractory to chemotherapy treatment . J. Clin. Oncol. , 16 , 2659 – 2671 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 46. ) Baselga , J. , Norton , L. , Albanell , J. , Kim , Y. M. and Mendelsohn , J.Recombinant humanized anti‐HER2 antibody (HERCEPTIN(tm)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts . Cancer Res. , 58 , 2825 – 2831 ( 1998. ). [PubMed] [Google Scholar]
  • 47. ) Moasser , M. M. , Basso , A. , Averbuch , S. D. and Rosen , N.The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2‐driven signaling and suppresses the growth of HER2‐overexpressing tumor cells . Cancer Res. , 61 , 7184 – 7188 ( 2001. ). [PubMed] [Google Scholar]
  • 48. ) Cuello , M. , Ettenberg , S. A. , Clark , A. S. , Keane , M. M. , Posner , R. H. , Nau , M. M. , Dennis , P. A. and Lipkowitz , S.Down‐regulation of the erbB‐2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor‐related apoptosis‐inducing ligand‐mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB‐2 . Cancer Res. , 61 , 4892 – 4900 ( 2001. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES